Company Defence Therapeutics Inc.

Equities

DTC

CA24463V1013

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Other Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange Other stock markets 20:59:00 03/05/2024 BST			5-day change	1st Jan Change
1.47 ^CAD	-9.26%		+17.60%	-36.91%

03-26	Defence Therapeutics Inc. Announces the Successful Testing of Second-Generation Anti-Cancer Vaccine, Called ARM-002TM	CI
03-01	Defence Therapeutics Inc. Announces Peer-Reviewed Publication on Accum-E7 Anti-Cancer Vaccine in Cancer Science Journal and Financing Update	CI

Defence Therapeutics Inc. is a Canada-based biotechnology company working on engineering vaccines and antibody drug conjugates (ADC) products using its proprietary platform. The Company is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological-/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. Its platform's core is the Accum technology, which enables delivery of vaccine antigens or ADCs in their intact form to target cells. The Company is focused on research, development and advancement of various products using its Accum technology, which include Dendritic Cell cancer vaccines using Accum (Accuvac); a new protein-based vaccine formulation against COVID and infectious diseases; ADC targeting various cancers; anti-cancer AccuTOX program; cervical cancer vaccine; mesenchymal stromal cell-based vaccine (ARM) targeting cancer, and messenger ribonucleic acid vaccination.

Managers	Title	Age	Since
Simon Beaudoin FOU	Founder	40	17/07/17
Sébastien Plouffe FOU	Founder	51	17/07/17
P. Meagher DFI	Director of Finance/CFO	39	17/09/20
Moutih Rafei CTO	Chief Tech/Sci/R&D Officer	42	08/10/20
Carrie Cesarone SEC	Corporate Secretary	58	-

Members of the board	Title	Age	Since
Sébastien Plouffe FOU	Founder	51	17/07/17
P. Meagher DFI	Director of Finance/CFO	39	17/09/20
Raimar Löbenberg CHM	Chairman	58	04/01/21
Moutih Rafei CTO	Chief Tech/Sci/R&D Officer	42	08/10/20
Sarkis Meterissian BRD	Director/Board Member	62	04/01/21
Riam Shammaa BRD	Director/Board Member	-	08/11/21
Kwin Grauer BRD	Director/Board Member	-	08/12/22

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	45,536,673	43,386,673 ( 95.28 %)	0	95.28 %

Name	Equities	%	Valuation
Sébastien Plouffe 3.553 %	1,600,000	3.553 %	2 M $
P. Meagher 0.8216 %	370,000	0.8216 %	462 500 $
Sarkis Meterissian 0.4263 %	192,000	0.4263 %	240 000 $
Carrie Cesarone 0.2576 %	116,000	0.2576 %	145 000 $
Raimar Löbenberg 0.2220 %	100,000	0.2220 %	125 000 $
Moutih Rafei 0.1554 %	70,000	0.1554 %	87 500 $
Simon Beaudoin 0.1110 %	50,000	0.1110 %	62 500 $
Kwin Grauer 0.0222 %	10,000	0.0222 %	12 500 $

Defence Therapeutics Inc

200 Burrard Street Suite 1680

V6C 3L6, Vancouver

http://www.defencetherapeutics.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
DEFENCE THERAPEUTICS INC.	-36.91%	48.81M
MODERNA, INC.	+25.69%	47.86B
LONZA GROUP AG	+46.90%	41.42B
IQVIA HOLDINGS INC.	-3.46%	40.66B
CELLTRION, INC.	-6.20%	28.92B
ICON PUBLIC LIMITED COMPANY	+9.17%	25.55B
ALNYLAM PHARMACEUTICALS, INC.	-20.42%	19.27B
BIO-TECHNE CORPORATION	+0.17%	12.15B
MEDPACE HOLDINGS, INC.	+28.07%	12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.24%	11.99B

Other Biotechnology & Medical Research